Chemo-immunotherapy treatment for chronic lymphocytic leukemia (CLL) induces high response rates and improves progression free (PFS) and overall survival (OS) as compared to chemotherapy alone. The fludarabine, cyclophosphamide, and rituximab (FCR) regimen is a standard first line and salvage treatment for CLL. However, FCR is associated with significant immunosupression and an increased risk of opportunistic infections (Ols). Here, we report a case of disseminated polyomavirus infection despite standard anti-infective prophylaxis in a relapsed CLL patient in a sustained clinical complete remission (CR) after FCR therapy.
PDF (416.64 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
I have had nothing but positive experiences publishing with Libertas Academica. The publication procedure is as quick and smooth as any I've encountered, and the peer review process is sufficiently rigorous that the reader can have complete confidence in the content of its journals.
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.See Our Results
Copyright © 2013 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)